10-Q: Amphastar Q2 2025: Revenue Dip Amid Strategic Shifts

Amphastar Pharmaceuticals reports a decline in net income and total revenues for Q2 2025, driven by product mix changes and increased operating expenses, despite strong BAQSIMI growth.

Summary

• Total net revenues for the three months ended June 30, 2025, decreased by 4% to $174.4 million, down from $182.4 million in the prior year period.
• Product revenues, net, for Q2 2025 were $174.4 million, a 3% decrease from $179.4 million in Q2 2024.
• BAQSIMI sales surged by 51% to $46.7 million in Q2 2025, up from $30.9 million in Q2 2024, due to the company assuming full global distribution responsibilities.
• Glucagon sales decreased by 25% to $20.6 million in Q2 2025, primarily due to a $4.7 million impact from lower average selling price and a $2.1 million impact from decreased unit volumes.
• Epinephrine sales fell by 42% to $16.2 million in Q2 2025, mainly due to decreased unit volumes from increased competition and other suppliers returning to historical distribution levels.
• Lidocaine sales increased by 17% to $15.0 million in Q2 2025, driven by higher unit volumes due to shortages from other suppliers.
• Net income for Q2 2025 was $31.0 million, an 18% decrease from $37.9 million in Q2 2024.
• Diluted earnings per share (EPS) for Q2 2025 were $0.64, down from $0.73 in Q2 2024.
• For the six months ended June 30, 2025, total net revenues decreased by 3% to $344.9 million, while net income dropped by 31% to $56.3 million.
• Research and development expenses increased by 14% to $20.1 million in Q2 2025 and by 16% to $40.2 million for the six months, primarily due to increased material and supply expenses for inhalation pipeline products and clinical trial costs.
• Selling, distribution, and marketing expenses rose by 14% to $10.2 million in Q2 2025, driven by expanded efforts for BAQSIMI and Primatene MIST.
• Net cash provided by operating activities for the six months ended June 30, 2025, was $70.7 million, a decrease from $124.4 million in the prior year period, mainly due to an increase in inventories.
• The Board of Directors authorized a $50.0 million increase to the share buyback program in August 2025, bringing the total authorization to $435.0 million.

Sentiment

Score: 4

Explanation: The financial results show a notable decline in net income, EPS, and overall revenue, despite strong performance from the BAQSIMI acquisition. Increased operating expenses, particularly in R&D and S&M, are impacting profitability. While strategic investments and a share buyback program are positive, the current financial performance and competitive pressures in key product areas present challenges, leading to a moderately negative sentiment.

Positives

• BAQSIMI sales increased significantly by 51% in Q2 2025 and 90% for the six months, benefiting from the company assuming full global distribution responsibilities.
• Lidocaine sales grew by 17% in Q2 2025 due to increased demand from competitor shortages.
• Primatene MIST sales showed a slight increase in Q2 2025 and a 10% increase for the six months, contributing to higher-margin product sales.
• The company launched Albuterol in August 2024, diversifying its product portfolio.
• A $50.0 million increase to the share buyback program was authorized, indicating management's confidence and commitment to returning value to shareholders.
• Interest expense decreased by 27% in both the three and six-month periods due to debt repayments and the full payment of the BAQSIMI deferred payment in June 2024.

Negatives

• Total net revenues decreased by 4% in Q2 2025 and 3% for the six months, primarily due to the reclassification of BAQSIMI revenues and declines in other key products.
• Net income decreased by 18% in Q2 2025 and 31% for the six months, indicating a significant impact on profitability.
• Diluted EPS declined to $0.64 in Q2 2025 from $0.73 in Q2 2024, and to $1.15 for the six months from $1.54.
• Gross profit decreased by 9% in Q2 2025 and 7% for the six months, with gross margins declining from 52% to 50% due to product mix changes and lower pricing for some higher-margin products.
• Glucagon sales decreased by 25% in Q2 2025 and 26% for the six months, attributed to lower average selling prices and unit volumes due to competition and a shift to ready-to-use products.
• Epinephrine sales dropped by 42% in Q2 2025 and 36% for the six months, impacted by increased competition and other suppliers returning to historical distribution levels.
• Net cash provided by operating activities decreased significantly by $53.7 million for the six months ended June 30, 2025, primarily due to increased inventories.
• Other revenues, which included BAQSIMI sales made by Lilly in the prior year, were zero in the current period, contributing to the overall revenue decline.

Risks

• Adverse impacts of global conflicts, challenging macroeconomic conditions, and market uncertainty on business, financial condition, operations, cash flows, and liquidity.
• Difficulty in attracting, hiring, and retaining highly skilled personnel.
• Interruptions to manufacturing and production due to natural catastrophic events, power disruptions, pandemics, wars, or terrorist attacks.
• Uncertainty regarding the timing and likelihood of U.S. Food and Drug Administration (FDA) approvals and regulatory actions on product candidates and manufacturing activities.
• Challenges in advancing product candidates through clinical trials and successfully commercializing them.
• Increased costs and delays resulting from extensive pharmaceutical regulations.
• Intense competition in the development and marketing of products and product candidates.
• Potential for adverse application of environmental, health, and safety laws and regulations.
• Uncertainty regarding market acceptance of new products and proprietary drug delivery technologies.
• Effects of reforms in healthcare regulations and reductions in pharmaceutical pricing, reimbursement, and coverage.
• Risk of significant price concessions or exclusion of suppliers adversely affecting the business.
• Variations in intellectual property laws and challenges in establishing, maintaining, and defending intellectual property protection.
• Potential for exposure to product liability claims.
• Challenges in successfully bidding for suitable acquisition targets or licensing opportunities, or integrating acquisitions.
• Difficulties in expanding internationally.
• Impact of trade tariffs, export or import restrictions, or other trade barriers, particularly concerning U.S.-China trade relations and tariffs on Chinese-origin items.
• Vulnerability to system breaches or failures, including cyber-attacks, data loss, and intellectual property theft, which could disrupt operations and incur significant costs.
• Risk of forced sale of common stock pledged as collateral by CEO and related parties for personal loans, which could cause the stock price to decline.

Future Outlook

The company anticipates that sales of glucagon will continue to decline due to competitive dynamics, and sales of epinephrine and other products will fluctuate based on competitor supply. Selling, distribution, and marketing expenses are expected to increase due to expanded efforts for BAQSIMI and Primatene MIST. Substantial investments in research and development are planned to expand the product portfolio, with R&D expenses expected to increase annually due to higher clinical trial costs for insulin and inhalation product candidates. The company believes its cash reserves, operating cash flows, and credit facilities will be sufficient to fund operations for at least the next 12 months, with additional cash flows expected from future product launches, though regulatory approval and timing are uncertain.

Management Comments

• "We anticipate that sales of glucagon will continue to decline in the future due to competitive dynamics."
• "We also anticipate that sales of epinephrine and other products will continue to fluctuate depending on the ability of our competitors to supply market demands."
• "We expect that selling, distribution and marketing expenses will continue to increase due to the increase in marketing expenditures for BAQSIMI and Primatene MIST."
• "Legal fees may fluctuate from period to period due to the timing of patent challenges and other litigation matters."
• "We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business."
• "We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates."
• "We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q."
• "We expect additional cash flows to be generated in the longer term from future product launches, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product launches, which could be lengthy or ultimately unsuccessful."

Industry Context

The biopharmaceutical industry is characterized by intense competition, significant regulatory hurdles, and ongoing pricing pressures. Amphastar's performance reflects these trends, with strong growth in its acquired BAQSIMI product offsetting declines in older, more competitive products like glucagon and epinephrine. The shift towards ready-to-use glucagon products, as mentioned in the filing, indicates a broader market trend towards more convenient and user-friendly drug delivery systems. Increased R&D spending is typical for companies aiming to expand their product pipeline and maintain competitiveness in a rapidly evolving market.

Corporate Governance

Legal Proceedings

• A former employee initiated an employment litigation on April 15, 2024, against Amphastar and IMS, with individual and class action claims for alleged violations of the California Labor Code (PAGA, wage and hour, other state laws). The individual and class claims were dismissed in November 2024, leaving only the PAGA claim.
• A former employee initiated an employment litigation on June 20, 2024, against Amphastar, IMS, and Roth Staffing Companies L.P., with individual and class action claims for alleged violations of the California Labor Code (wage and hour, other state laws).
• The company is subject to a lawsuit for a property and casualty claim, with an estimated liability of $11.0 million recorded as of June 30, 2025, which is fully covered by the company's insurance policies.

Related Party Transactions

• The company has an 11.5% ownership in Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (Hanxin), which is accounted for as an equity method investment. Henry Zhang (son of Dr. Jack Zhang) is an equity holder, general manager, and chairman of Hanxin's board. Dr. Mary Luo and Dr. Jack Zhang also have an ownership interest in Hanxin through an affiliated entity.
• Contract manufacturing agreements with Hanxin: The company recognized $0.3 million in revenue from manufacturing services provided to Hanxin during Q2 2025 and $0.4 million for the six months ended June 30, 2025. Receivables from Hanxin were approximately $0.5 million as of June 30, 2025.
• Contract research agreement with Hanxin: In July 2022, the company entered a three-year agreement for Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and perform scale-up manufacturing process development. The company paid an immaterial amount under this amended agreement during the six months ended June 30, 2025.
• Supply agreement with Nanjing Letop Biotechnology Co., Ltd. (Letop): In November 2022, the company entered a three-year supply agreement with Letop (related party due to Henry Zhang's ownership) for chemical intermediates on a cost-plus basis, not to exceed $1.5 million. The company paid an immaterial amount under this agreement during Q2 2025 and the six months ended June 30, 2025.
• Primatene MIST Distribution Agreement with Hong Kong Genreach Limited (Genreach): In August 2024, the company appointed Genreach (wholly owned subsidiary of Hanxin) as the exclusive distributor for Primatene MIST in Greater China. No revenue was recognized from this agreement during Q2 2025 or the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Impacted by declining net income and EPS, but potentially benefit from the increased share buyback program. The risk of forced stock sales by management due to pledged shares could negatively affect share price.
• Employees: Affected by increased salary and personnel-related expenses, and benefit from the 401(k) plan and deferred compensation plan. Employee litigations indicate potential workplace issues.
• Customers: Benefit from increased availability of BAQSIMI due to the company assuming full distribution. May experience fluctuations in supply for epinephrine and other products depending on competitor dynamics.
• Suppliers: The company's dependence on single or limited sources for raw materials and APIs, especially foreign sources, poses a risk to supply chain stability.
• Creditors: The company remains in compliance with all debt covenants, indicating stable creditworthiness, but the fair value of convertible notes is below principal amount.

Next Steps

• Continue substantial investments in research and development to expand the product portfolio and grow the business.
• Increase marketing expenditures for BAQSIMI and Primatene MIST.
• Monitor and manage fluctuating sales of epinephrine and other products based on competitor supply.
• Address the anticipated decline in glucagon sales due to competitive dynamics.
• Evaluate the impact of the 'One Big Beautiful Bill Act' on consolidated financial statements.
• Recognize unrecognized compensation cost related to non-vested stock options and RSUs over weighted-average periods of 2.8 years.
• Begin monthly lease payments of $0.3 million for the new Rancho Cucamonga facility starting January 1, 2026.

Key Dates

Recommendation

Amphastar Pharmaceuticals presents a mixed financial picture. While key products like BAQSIMI are experiencing significant growth due to strategic shifts in distribution, overall net income and EPS have declined year-over-year, impacted by increased operating expenses and competitive pressures on other products like glucagon and epinephrine. The company is making substantial R&D investments for future growth and has authorized an increased share buyback program, which are positive signals. However, the current profitability contraction and ongoing competitive dynamics warrant caution. A 'hold' recommendation is appropriate for investors to observe if the strategic investments and BAQSIMI's continued growth can offset declines in other segments and lead to improved overall profitability in future periods, while acknowledging the inherent risks in the pharmaceutical industry and specific company-related factors like executive stock pledges.

Keywords

Pharmaceuticals, Biopharmaceutical, Generic Drugs, Injectable Products, Inhalation Products, Intranasal Products, Insulin API, BAQSIMI, Primatene MIST, Glucagon, Epinephrine, Lidocaine, ANDA, BLA, Biosimilar, FDA Approval, Clinical Trials, Drug Manufacturing, Supply Chain, SEC Filing, 10-Q, Financial Results, Earnings, Revenue, Profitability, Research and Development, Share Buyback, Corporate Governance, Risk Management